» Articles » PMID: 3922392

Pharmacokinetics and Haemodynamic Effects of Tocainide in Patients with Acute Myocardial Infarction Complicated by Left Ventricular Failure

Overview
Specialty Pharmacology
Date 1985 Apr 1
PMID 3922392
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetics and haemodynamic effects of tocainide, an orally active structural analogue of lignocaine, were studied in patients with acute myocardial infarction complicated by left ventricular failure. Fourteen patients (mean age 65 years) with acute myocardial infarction complicated by mild left ventricular failure were studied, following a single dose of tocainide (250 mg) by intravenous infusion, over 30 min. Heart rate, systemic arterial pressure, pulmonary artery pressure and cardiac output were monitored. Plasma tocainide levels were estimated by gas chromatography. The mean plasma level of tocainide achieved was 2.95 micrograms/ml (15.37 mmol/l). The mean plasma half-life was 15.6 h. The mean cardiac index was reduced 5 min after completion of the infusion, from 2.24 1 min-1 m-2 (+/- 0.40) to 2.07 1 min-1 m-2 (+/- 0.29) (P less than 0.01). At 90 min the cardiac index had returned to pre-treatment levels. Small changes were seen in the heart rate, arterial blood pressure and the pulmonary artery pressure but these changes were not statistically significant. The pharmacokinetics of tocainide were not significantly altered in patients with acute myocardial infarction complicated by mild left ventricular failure.

Citing Articles

Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Ogawa R, Stachnik J, Echizen H Clin Pharmacokinet. 2013; 52(3):169-85.

PMID: 23344981 DOI: 10.1007/s40262-012-0029-2.


Clinical pharmacokinetics in heart failure. An updated review.

Shammas F, Dickstein K Clin Pharmacokinet. 1988; 15(2):94-113.

PMID: 3064953 DOI: 10.2165/00003088-198815020-00002.


Effects of cardiovascular disease on pharmacokinetics.

Rodighiero V Cardiovasc Drugs Ther. 1989; 3(5):711-30.

PMID: 2577313 DOI: 10.1007/BF01857622.


Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Bauman J, Schoen M, Hoon T Clin Pharmacokinet. 1991; 20(2):151-66.

PMID: 2029806 DOI: 10.2165/00003088-199120020-00006.

References
1.
Forrester J, Ganz W, Diamond G, McHugh T, Chonette D, Swan H . Thermodilution cardiac output determination with a single flow-directed catheter. Am Heart J. 1972; 83(3):306-11. DOI: 10.1016/0002-8703(72)90429-2. View

2.
Collinsworth K, Kalman S, Harrison D . The clinical pharmacology of lidocaine as an antiarrhythymic drug. Circulation. 1974; 50(6):1217-30. DOI: 10.1161/01.cir.50.6.1217. View

3.
Roberts R, Husain A, Ambos H, Oliver G, COX Jr J, Sobel B . Relation between infarct size and ventricular arrhythmia. Br Heart J. 1975; 37(11):1169-75. PMC: 482935. DOI: 10.1136/hrt.37.11.1169. View

4.
McDevitt D, Nies A, Wilkinson G, Smith R, Woosley R, OATES J . Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man. Clin Pharmacol Ther. 1976; 19(4):396-402. DOI: 10.1002/cpt1976194396. View

5.
Prescott L, Pottage A, Clements J . Absorption, distribution and elimination of mexiletine. Postgrad Med J. 1977; 53 Suppl 1:50-5. View